Objective
We will develop a new class of ant malarial drug that target membrane biogenesis of the erythrocyte stage of Plasmodium falciparum. We have established thatphospholipid synthesis of the parasite, but not the host, is specifically blocked, and that multiresistant malaria is susceptible. To date no resistance has been found. Efficacy and tolerance in mice, dogs, and primates have encouraged drug development for clinical testing. Here we will optimise currently promisingprodrugs and select one candidate for rapid transfer to preclinical studies. We will also assess promising new molecular leads and oral delivery systems. Complementary research will define the molecular mechanisms of drug activity and will more fully characterise parasite serine lipid metabolism. This is unattractive pathway for drug development that is absent in mammalian cells and that offers considerable potential for medium-term pharmacological interventions .
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological scienceszoologymammalogyprimatology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseasesmalaria
- agricultural sciencesanimal and dairy sciencedomestic animals
- natural sciencesbiological sciencesbiochemistrybiomoleculeslipids
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
34095 MONTPELLIER
France